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comes to the choice of the method of analysis. Cases of disagreement between 
G-BA and IQWiG are rarer in this area. In the case of Belimumab, the manufacturer 
chose to demonstrate the additional benefit by showing the add-on effect of the 
agent on-top of the appropriate comparator and not against it. This resulted in 
diverging benefit assessment by IQWiG and G-BA. ConClusions: The analysis 
of the assessment for all new active agents shows disparities between the assess-
ments of all parties involved. The AMNOG legislation has been in place for about 
two years and still, there are uncertainties in the choice of patient-relevant end-
points, comparators and method of analysis in the German benefit assessment 
process. Discussion is necessary to resolve diverging expectations about required 
methods and following assessments.
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objeCtives: To estimate the potential impact of the new health economic assess-
ment requirement on innovative products that came into law in October 2012 in 
France, by comparing the outcomes of recent Health Technology Assessments 
(HTA) in France (HAS) and the UK (NICE, SMC, AWMSG, JCVI). The hypothesis is 
that reimbursed products that achieved a high benefit score in France may have 
been rejected if the health economic case had to be demonstrated, as is required in 
the UK. Methods: A search was conducted to identify all therapies evaluated by 
HAS which were given a significant, important or moderate therapeutic improve-
ment score (ASMR I, II or III) between January 2010-June 2013. We then identified 
the assessments of the same product in the UK and compared the outcome of the 
assessment and the role of the economic evidence that was submitted. Results: 
Thirty-six therapies rated an ASMR I-III by HAS were found. Out of these 36, 19 
products had not (yet) been evaluated in the UK. For the remaining 17 that had 
been assessed by both countries, only one was not recommended by at least one of 
the UK agencies. NICE’s primary reason for rejecting the said intervention was due 
to the ‘clinical and cost effectiveness’. Similarly the SMC stated the economic case 
of the drug had ‘not been demonstrated’, and the long term clinical effect remains 
unknown. ConClusions: Initially, it doesn’t appear that economic evaluations 
based on QALYs considerably influence the outcomes of HTAs. Only one assessment 
was rejected by both UK agencies based on economic grounds but was awarded an 
ASMR III. Since most products have been endorsed by the UK agencies, the French 
system’s incorporation of health economics will not necessarily be an additional 
hurdle that cannot be overcome.
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Web-based of ToPIc selecTIon foR comPaRaTIve effecTIveness 
ReseaRcH In KoRea
Kim H.S., Lee D.S., You J.H.
National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea
objeCtives: As the only health technology evaluation institution in Korea, National 
Evidence-based Healthcare Collaborating Agency has made efforts to establish the 
topic selection model of comparative effectiveness research which corresponds to 
Korean situations in order to revitalize it since 2012. Methods: As a result of pre-
paring thetopic selection process of the comparative effectiveness research accord-
ing to these efforts and of conducting model operations in 2012, solution to access 
to the proposal process of research topics and a close examination of research 
methodologies was proposed as improvement point. Results: Accordingly, web-
based research topic proposal systems(www.necacer.re.kr) were designed in order 
to solve access to the proposal process of research topics and to increase trans-
parency of the early stage of research in 2013. To make a close examination of 
the possibility of research performance in multidisciplinary fashion, evaluation 
systems of three stages were divided to operate but web-based design which is the 
same as topic proposal systems was done reflecting the evaluator’s geographical 
access etc. Concretely, web-systems for topic proposal are composed of writing 
proposed research topic, writing proposed content of a topic, and confirming and 
submitting stages after writing basic information after login, and evaluative web 
systems were composed as follows: Step 1 is composed of quantitative evalua-
tion based on 6 standards, step 2 qualitative evaluation based on 6 standards, and 
step 3 investigation process based on 4 standards in relation to research topics 
refined. ConClusions: It is conceived that Korean web-based topic selection sys-
tems of comparative effectiveness research prepared systematically taking Korean 
situation into consideration will be able to contribute to improving qualitative 
aspects of research and enhancing researchers’ credibility by transparent opening 
the whole process of proposing, selecting and confirming topics.
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objeCtives: Early benefit assessment in Germany under the AMNOG legislation 
requires a direct comparison with the appropriate comparator determined by the 
Federal Joint Committee (G-BA). In case no head-to-head studies are available, sub-
mission of indirect comparisons is permitted to assess the additional benefit of the 
new drug. The aim of this study was to comprehensively analyze the submissions 
of indirect comparisons reviewed so far by the Institute for Quality and Efficiency 
in Health Care (IQWiG) from January 2011 until May 2013. Methods: A systematic 
review of all 48 published assessment reports was performed. Results: There is 
a mismatch between the original intention of the early benefit assessment and 
its actual outcome. Until May 2013, 14 indirect comparisons have been conducted 
and submitted by manufacturers regarding the early benefit assessment. Only one 
indirect comparison has been accepted in a subindication by the IQWiG. However 
to obtain a positive decision and the number of unique drugs reviewed within the 
disease condition (r= .46 and .41, respectively). This relationship was not observed 
for PBAC (r= 0.01). ConClusions: PBAC required a greater number of submissions 
to gain a positive decision and the lag time to a positive decision is longer compared 
to SMC and CADTH. The number of submissions needed to gain a positive decision 
by CADTH and SMC were similar, but CADTH’s lag time was double that of SMC. For 
both SMC and CADTH, the number of drugs reviewed in a disease condition was 
positively correlated with the number of times a drug had to be submitted in order 
to gain a positive decision.
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objeCtives: The study sought to establish the pattern by which draft versus final 
technology appraisal’s (TA) for drugs have been issued by UK’s NICE. In particular, 
the study focused on variations between the draft versus final guidance, and the 
rationale for any changed recommendations during the appraisal process. Methods: 
The current study is based on a review of NICE’s 13 draft guidance and subse-
quent final guidance issued over the time period from November 2010 to mid June 
2013. Results: NICE issued five recommendations, four rejections and four rec-
ommendations subject to restriction, on drugs for use within the NHS in England 
and Wales. Four out of the five final recommendations had been overturned from 
an initial non- recommendation, to gaining a positive decision in final guidance. 
Meanwhile, all four final rejections corresponded to the recommendations made in 
its respective draft guidance. With one exception, all recommended drugs had an 
ICER below GBP30,000. None of the drugs rejected in the final guidance had a Patient 
Access Scheme offered. ConClusions: One-third of the 13 decisions were positive 
recommendations, a trend that is significantly lower than the average between 1 
March 2000 to 31 May 2013, when 62% of TA’s gained a positive final recommendation. 
Aside from clinical issues, the overriding rationale for the rejections were attributed 
to the high ICERs, coupled with the lack of PAS. This is compared to the case of, for 
example, ipilimumab, where a PAS offered in the final guidance lowered the ICER 
from GBP54,000 - GBP70,000 per QALY gained to GBP42,200 and essentially overturned 
NICEs initial non-recommendation. As seen in half of the initial rejections, NICE has 
overturned several decisions in favour of the manufacturer prior to final guidance.
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objeCtives: To compare how different European HTA agencies assess surrogate 
endpoints to demonstrate efficacy. Methods: We identified 8 therapies with sur-
rogate endpoints that were evaluated in the last 6 years by NICE and/or SMC (UK), 
HAS (France) and G-BA (Germany). The acceptability of the use of surrogate end-
points and any specific comments made by these agencies were analysed. Results: 
Commonly used surrogate endpoints such as glycated haemoglobin (HbA1c) in 
diabetes, progression free survival (PFS) in oncology and forced expiratory volume 
(FEV1) for respiratory diseases have been generally accepted as sufficient evidence 
to gain reimbursement by HTA agencies. Especially when a surrogate endpoint 
has been accepted by EMA, it is usually considered a valid outcome measure. Less 
well-accepted were several surrogate cardiovascular endpoints such as 6 minute 
walk test, blood pressure and LDL cholesterol. For G-BA it is important that sur-
rogate endpoints have been properly validated and are patient relevant but they 
did accept endpoints such as sustained virological response (SVR) for hepatitis 
treatments, FEV1 and body mass index (BMI) based on minor evidence. NICE and 
SMC also strongly value evidence to demonstrate the correlation between surro-
gate endpoints and clinical outcomes. Interestingly SMC has recently become more 
cautious in accepting widely established endpoints such as HbA1c. With regards 
to the HAS, they often did not comment on the use of surrogate endpoints at all 
in their published reports. ConClusions: The use of surrogate endpoints in the 
assessment of clinical benefit is still controversial; however, attempts are made to 
establish clearer regulations such as the recently published EUnetHTA guidelines 
regarding surrogate endpoints. In the absence of evidence on final patient-relevant 
clinical endpoints, several commonly used biomarkers and intermediate endpoints 
will be considered as valid surrogate endpoints by HTA agencies. Newer, less estab-
lished surrogate endpoints will be more subject to strict validation requirements.
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objeCtives: In the German HTA process (AMNOG) the choice of the patient-
relevant endpoint, the appropriate comparator and the method of analysis are 
known to be decisive for the G-BA’s resolution of an additional benefit. Therefore, 
we aimed to analyze differences between manufacturer’s dossiers and G-BA / 
IQWiG assessments. Methods: The analysis will take into account all completed 
AMNOG assessment procedures. We analyzed all G-BA resolutions in compari-
son to IQWiG assessments and the manufacturer. Results: One major point of 
discrepancies occurred in the declaration of patient-relevant endpoints. By June 
2013, 58 surrogate endpoints were declared by IQWiG and manufacturers mainly 
in the indications oncology, infectious diseases and diabetes. The G-BA clearly 
states that only valid patient relevant endpoints are to be considered. However, 
there remains uncertainty around the term “patient-relevant” and which criteria 
have to be met for the IQWiG to accept an endpoint as patient-relevant. To date, 
54 comparisons were made in the dossiers to show an additional benefit of a new 
agent. The pharmaceutical manufacturer and the IQWiG often disagree when it 
